Discovery of Hippo signaling as a regulator of CSPG4 expression and as a therapeutic target for Clostridioides difficile disease
PLOS Pathogens · 2023
DOI: 10.1371/journal.ppat.1011272 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS Pathogens, 2023. Verfasst von Jason L Larabee und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology and Immunology, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States of America. Hauptthemen laut MEDLINE: Clostridioides difficile, Bacterial Toxins. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, NIAID NIH HHS, Division of Intramural Research, National Institute of Allergy and Infectious Diseases.
Abstract (Originalsprache)
The signaling pathways and networks regulating expression of chondroitin sulfate proteoglycan 4 (CSPG4), a cancer-related protein that serves as a receptor for Clostridiodes difficile TcdB, are poorly defined. In this study, TcdB-resistant/CSPG4-negative HeLa cells were generated by exposure to increasing concentrations of the toxin. The cells that emerged (HeLa R5) lost expression of CSPG4 mRNA and were resistant to binding by TcdB. mRNA expression profiles paired with integrated pathway analysis correlated changes in the Hippo and estrogen signaling pathways with a CSPG4 decrease in HeLa R5 cells. Both signaling pathways altered CSPG4 expression when modulated chemically or through CRISPR-mediated deletion of key transcriptional regulators in the Hippo pathway. Based on the in vitro findings, we predicted and experimentally confirmed that a Hippo pathway inactivating drug (XMU-MP-1) provides protection from C . difficile disease in a mouse model. These results provide insights into key regulators of CSPG4 expression and identify a therapeutic for C . difficile disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Microbiology and Immunology, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States of America.
- Laboratory for Molecular Biology and Cytometry Research, Harold Hamm Diabetes Center, Oklahoma City, Oklahoma, United States of America.
- Department of Cell Biology, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States of America.
- Department of Pediatrics, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States of America.
ORCID-Profile: Jimmy D Ballard
Förderung
- NIGMS NIH HHS
- NIAID NIH HHS
- Division of Intramural Research, National Institute of Allergy and Infectious Diseases
- National Institute of General Medical Sciences
Zitieren
APA
Larabee, J. L., Doyle, D. A., Ahmed, U. K. B., Shadid, T. M., Sharp, R. R., Jones, K. L., Kim, Y. M., Li, S., & Ballard, J. D. (2023). Discovery of Hippo signaling as a regulator of CSPG4 expression and as a therapeutic target for Clostridioides difficile disease. PLOS Pathogens. https://doi.org/10.1371/journal.ppat.1011272
Vancouver
Larabee JL, Doyle DA, Ahmed UKB, Shadid TM, Sharp RR, Jones KL, et al. Discovery of Hippo signaling as a regulator of CSPG4 expression and as a therapeutic target for Clostridioides difficile disease. PLOS Pathogens. 2023. doi:10.1371/journal.ppat.1011272
BibTeX
@article{Larabee2023,
author = {Larabee, Jason L and Doyle, D Annie and Ahmed, Ummey Khalecha Bintha and Shadid, Tyler M and Sharp, Rachel R and Jones, Kenneth L and Kim, Young Mi and Li, Shibo and Ballard, Jimmy D},
title = {Discovery of Hippo signaling as a regulator of CSPG4 expression and as a therapeutic target for Clostridioides difficile disease},
journal = {PLOS Pathogens},
year = {2023},
doi = {10.1371/journal.ppat.1011272}
}
EUVIMED